Although stem cells were initially thought to be the magic bullet for numerous diseases, translation of a stem cell–based cure into the clinic is still a work in progress. Basic research is shedding light into the potential of stem cells, and different research fronts are now exploring how to exploit this potential to tackle diverse conditions. In 'Bench to Bedside', Akemi Tanaka, Mark Sauer, Dieter Egli and Daniel Kort discuss how genome transfer from eggs of mothers with mutated mitochondria into an enucleated egg from a healthy female donor at an early developmental stage can eliminate mitochondrial disease. The negligible mutant mitochondrial DNA carryover and the differentiation of subsequent embryonic stem cells into various cell types with healthy mitochondrial DNA content suggest this could be used to prevent transmission of mitochondrial disease to the offspring. The authors discuss safety concerns and remaining technical questions that need to be resolved to make way for this new technology in the clinic. In 'Bedside to Bench', Nan Yang and Marius Wernig peruse a small study of children with a myelin disorder showing that transplantation of human neural stem cells leads to engraftment and donor cell–derived myelination.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Overcoming bioethical, legal, and hereditary barriers to mitochondrial replacement therapy in the USA
Journal of Assisted Reproduction and Genetics Open Access 15 December 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Elliott, H.R., Samuels, D.C., Eden, J.A., Relton, C.L. & Chinnery, P.F. Am. J. Hum. Genet. 83, 254–260 (2008).
Schaefer, A.M. et al. Ann. Neurol. 63, 35–39 (2008).
Treff, N.R. et al. Fertil. Steril. 98, 1236–1240 (2012).
McGrath, J. & Solter, D. Science 220, 1300–1302 (1983).
Sato, A. et al. Proc. Natl. Acad. Sci. USA 102, 16765–16770 (2005).
Craven, L. et al. Nature 465, 82–85 (2010).
Tachibana, M. et al. Nature 461, 367–372 (2009).
Paull, D. et al. Nature 493, 632–637 (2013).
Tachibana, M. et al. Nature 493, 627–631 (2013).
Poulton, J. et al. PLoS Genet. 6, e1001066 (2010).
Reinhardt, K., Dowling, D.K. & Morrow, E.H. Science 341, 1345–1346 (2013).
Sharpley, M.S. et al. Cell 151, 333–343 (2012).
Lee, H.S. et al. Cell Rep. 1, 506–515 (2012).
Baylis, F. Reprod. Biomed. Online 26, 531–534 (2013).
Johnson, M.H. Reprod. Biomed. Online 26, 516–519 (2013).
Nuffield Council on Bioethics. http://www.nuffieldbioethics.org/mitochondrial-dna-disorders/ (2012).
Human Fertilisation and Embryology Authority. http://www.hfea.gov.uk/docs/Mitochondria_replacement_consultation_-_advice_for_Government.pdf (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Tanaka, A., Sauer, M., Egli, D. et al. Harnessing the Stem Cell Potential: The path to prevent mitochondrial disease. Nat Med 19, 1578–1579 (2013). https://doi.org/10.1038/nm.3422
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3422
This article is cited by
-
Overcoming bioethical, legal, and hereditary barriers to mitochondrial replacement therapy in the USA
Journal of Assisted Reproduction and Genetics (2019)